Pharmaron Beijing Co., Ltd. (HKG:3759)

Market Cap	59.41B +20.9%
Revenue (ttm)	15.69B +14.8%
Net Income	1.85B -7.2%
EPS	1.05 -7.1%
Shares Out	n/a
PE Ratio	32.09
Forward PE	24.93
Dividend	0.22 (1.03%)
Ex-Dividend Date	Jul 4, 2025

Volume	3,673,465
Average Volume	6,069,483
Open	21.22
Previous Close	21.22
Day's Range	21.10 - 21.64
52-Week Range	12.14 - 30.12
Beta	0.91
RSI	58.41
Earnings Date	Mar 30, 2026

About Pharmaron Beijing

Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Manufacturing Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy Services; and Others. The company offers laboratory chemistry and biological science services, including small molecule chemical drugs, oligonucleot...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 25,088
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 3759

Financial Performance

In 2025, Pharmaron Beijing's revenue was 14.10 billion, an increase of 14.82% compared to the previous year's 12.28 billion. Earnings were 1.66 billion, a decrease of -7.22%.

Financial numbers in CNY